Researchers all over the world are constantly gathering clinical data on the endocannabinoid system, cannabinoid synthesis, and a number of other important aspects of the cannabis plant.


Yet due to nearly a century of cannabis prohibition, America is only just now catching up to the scientific understanding we should have acquired long before 2016.

A major problem is that the government agencies responsible for considering the medical benefit of cannabis are apprehensive. In most cases, these regulators are stubbornly stuck on biased studies conducted during the heyday of the War on Drugs.

Even with hundreds of clinical examples of the benefits of the plant, cannabis remains listed as a Schedule I drug. Here is the criteria that defines a Schedule I drug:

“Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.” Schedule I Definition

Twenty-four states and the District of Columbia have passed legislation granting patients lawful access to cannabis medicine. Things are by no means perfect, but the overhyped fears are proving to be irrational. The sky has not fallen, in fact, tax revenues from recreational cannabis sales make headlines month over month.

Just to recap: Cannabis is a taxable cash crop that has both medical and recreational potential, and the Feds refuse to budge until they are presented with satisfactory medical evidence. The United States government has yet to be satisfied.

U.S. Senator Cory Booker (D-NJ) (L-R), Senator Rand Paul (R-KY), and Senator Kirsten Gillibrand (D-NY) hold a news conference, to introduce legislation that would prevent the federal government from prosecuting medical marijuana users in states where it is legal, at the U.S. Capitol in Washington, March 10, 2015. REUTERS/Jonathan Ernst (UNITED STATES - Tags: POLITICS HEALTH SOCIETY) - RTR4ST85

Fighting for Medical Cannabis: (L to R) Senator Booker (D-NJ), Senator Paul (R-KY), and Senator Gillibrand (D-NY) (source)

Yet the medical efficacy of cannabis has been proven. Time and time again. In countries all over the world. So how much cannabis science is enough?

Even U.S. Senators are voicing their concerns about the sluggish reconsideration of cannabis laws. Thankfully, reform advocates like Paul Armentano are bringing to light the ludicrous nature of the Federal Government’s cannabis policy.

Paul Armentano: Countering Common Misconceptions about Medicinal Cannabis


At the ShareFax community event last April, NORML’s deputy director, Paul Armentano, gave a compelling presentation on the facts and fears that continue to surround cannabis. You can view the full video of Armentano’s speech below, or on our Youtube channel.

Armentano does a wonderful job of addressing the common myths that are associated with cannabis:

  • Medical cannabis is too dangerous to recommend as a medicine
  • Medical cannabis poses too many unwanted side effects
  • Scientists have not adequately studied cannabis
  • Scientists do not yet know the long-term effects of cannabis
  • There are not sufficient clinical trials evaluating medical cannabis
  • No major medical or health organizations support access to medical cannabis
  • No medicine is smoked
  • Marinol is already available
  • Physicians do not ‘prescribe’ cannabis
  • Cannabis is not medicine because it has not been approved by the FDA

By devoting several slides to each one of these misconceptions, Armentano provides foundational evidence to remove cannabis from the Schedule I drug classification imposed by the DEA.


So back to the original question: How much cannabis science does the government need to see? Many drugs have been approved by the FDA from a single clinical trial, often without any diversity between the subjects being tested.

Cannabis has been around for thousands of years, used by millions, and has yet to be the direct cause of death since the beginning of modern medical reports. Cannabis passed the FDA’s drug review process before the FDA was even a twinkle in Democracy’s eye.

Deputy Direct of NORML, Paul Armentano (L)

Advocates like Paul Armentano are supporting the cannabis community in a big way. The Cannabis Reports team is thrilled to have had the opportunity to film the ShareFax event so that people everywhere have access to authoritative cannabis information.

For the most up to date info on Cannabis Reports, follow us on Twitter, and like us on our Facebook page.